Gilead Sciences, Inc. and Kymera Therapeutics, Inc have agreed to jointly develop and commercialise a novel molecular glue degrader (MGD) programme targeting cyclin-dependent kinase 2 (CDK2) for oncology indications.
The small molecule treatment provides a new mechanism of action. Instead of inhibiting CDK2, which can lead to side effects, the drug removes CDK2 from cells.